Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Emerging SARS-CoV-2 Resistance After Antiviral Treatment

JAMA Network Open(2024)10.1001/jamanetworkopen.2024.35431Source: DataRank Database

Emerging SARS-CoV-2 Resistance After Antiviral Treatment is a research paper published in JAMA Network Open (2024). On theSindex it has a DataRank of 0. It has been cited 45 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access45 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 14.59)OA: goldTopics (68)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (28)

Manish C. Choudhary ORCID,Rinki Deo,Fizah Yousuf,A. Gomez ORCID,Gregory E. Edelstein

Live enrichment

PubMed:39320890 PMC:PMC11425144 OpenAlex:https://openalex.org/W4402824995

NIAID NIH HHS

Grant: P30 AI060354

NIAID NIH HHS

Grant: R01 AI176287

NIAID NIH HHS

Grant: R24 AI136618

NIAID NIH HHS

Grant: U19 AI110818

National Institutes of Health

Grant: 5R01AI176287-03

Characterization of Persistent COVID-19

National Institutes of Health

Grant: 5P30AI060354-18

Harvard University Center for AIDS Research

National Institutes of Health

Grant: 2U19AI110818-06

Advancing Genomic Technologies to Combat Infectious Disease: Mapping Dynamics within Single Cells, Individual Hosts, and Global Populations

FWCI

14.59

Citation Percentile

1.0%

Influential Citations

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://jamanetwork.com/journals/jamanetworkopen/articlepdf/2824050/tamura_2024_oi_241054_1726669148.41936.pdf

GOLDhttps://doi.org/10.1001/jamanetworkopen.2024.35431

publisherhttps://jamanetwork.com/journals/jamanetworkopen/articlepdf/2824050/tamura_2024_oi_241054_1726669148.41936.pdf

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39320890

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11425144

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Medicine0303 health sciences03 medical and health sciencesHumansFemaleMaleAntiviral AgentsSARS-CoV-2Drug Resistance, ViralMiddle AgedAlanineCOVID-19 Drug TreatmentAdenosine MonophosphateAdultMutationCOVID-19AgedCohort Studies

MeSH Terms

COVID-19SARS-CoV-2COVID-19 Drug TreatmentAdenosine MonophosphateAdultAgedAlanineAntiviral AgentsFemaleHumansMaleMiddle AgedMutationCohort StudiesDrug Resistance, Viral

Keywords

MedicineResistance mutationRegimenInternal medicineViral loadPopulationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CohortCohort studyImmunologyCoronavirus disease 2019 (COVID-19)VirusBiologyDiseaseInfectious disease (medical specialty)Polymerase chain reactionMaleAdultAlanineSARS-CoV-2COVID-19Middle AgedAntiviral AgentsAdenosine MonophosphateCOVID-19 Drug TreatmentCohort StudiesDrug Resistance, ViralMutationHumansFemaleOriginal InvestigationAged

Sustainable Development Goals

SDG 0: Good health and well-being

Emerging SARS-CoV-2 Resistance After Antiviral Treatment

FAIR Checklist

Authors (28)

Funding (7 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)